There is a huge disconnect between aging research in the lab and medical practitioners who directly deal with patients. Aging research labs around the world are often years ahead of overall medical knowledge, and this is a serious problem in the drive to create a comprehensive longevity ecosystem.
To address this, there needs to be a bridge between current academic research and front-line physicians. With this in mind, Deep Longevity has launched a new introductory course to help physicians get up to speed with this rapidly progressing field. This will provide the foundation for a greater understanding of longevity medicine, starting with the basics and moving ahead to further Continuing Medical Education-accredited chapters in the curriculum.
Introduction to Longevity Medicine for Physicians, part of the Longevity Medicine Course, will launch on the LabXchange platform. This course provides a comprehensive longevity medicine curriculum for clinicians, covering the topics of biogerontology, geroscience and AI-based medicine along with a broad foundation of translational aging research terminology, theories and hallmarks of aging, basic aging pathways and mechanisms behind possibly geroprotective interventions, various types of aging clocks, and more.
This is an important milestone in the development of structured courses about longevity research and a step towards more synchronized thinking between academics and physicians. Such initiatives help to provide a foundation for building a future longevity ecosystem and to help healthcare adapt to a future in which aging is treated very differently.
If you are a physician and are interested in this course, or if you know a physician who might be interested, you can find out more information and how to enroll here. You can find the salient parts of the press release below.
Deep Longevity Inc, a company mainly engaged in the development of explainable artificial intelligence systems to track aging rates on multiple levels, announced the launch of the first Longevity Medicine course for Physicians. It is the first of several Longevity Medicine chapters, with upcoming courses scaled for scientists and patients.
This course is aimed to fill the educational gap in translation longevity medicine. Deep Longevity, a leader in artificial intelligence for the development of biomarkers of aging and longevity, brought together scientists and physicians engaged in basic and translational research to develop the course: “Longevity Medicine for Physicians”. The course covers basics in translational aging research from terminology and demographic aspects, theories and hallmarks of aging, basic aging pathways and mechanisms behind the possibly geroprotective interventions, and covers the various types of aging clocks.
The course is intended for medical professionals and students, who have limited time and seek a comprehensive, well-structured, reliable course. It contains three hours of core lectures providing an introduction to the field, lecture slides, lecture notes, quizzes, guest lectures, as well as references to additional reading materials and online resources. Introduction to Longevity Medicine is the first course in a series intended to provide advanced physicians with the latest approaches in longevity technology.
“As we are partnering with the advanced clinical institutions we see the gap between translational research and clinical practice and would like to provide the MDs with the resources they need to get into the rapidly growing field of longevity medicine, learn about the latest advances in artificial intelligence and in the pharmaceutical industry”, said Alex Zhavoronkov, PhD, the founder of the Longevity Medicine course and Chief Longevity Officer at Deep Longevity.
“While much-scattered information is available from more or less evidence-based sources, there was a lack of a structured, guided and well organised course that provides physicians with the necessary background information on this rapidly evolving discipline of healthy longevity. This is why we developed this very first course in Longevity Medicine – to close this gap and provide understandable and practicable, credible resources for clinicians”, said Evelyne Bischof, MD, co-founder of the course.
Earlier this year, Deep Longevity received investments from expert longevity investment funds related to clinical organizations and is currently subject to a conditional acquisition by Regent Pacific Group Limited (SEHK:0575.HK), a public company whose securities are listed on The Stock Exchange of Hong Kong Limited. It also announced a partnership with Human Longevity Inc, one of the world’s most advanced centers for preventative diagnostic medicine. Since then, it has partnered with several other advanced clinics and hospitals.